Company Description
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.
It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product.
The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019.
Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
| Country | United States |
| Founded | 2006 |
| IPO Date | Feb 3, 2011 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 712 |
| CEO | Frank D. Lee |
Contact Details
Address: 5401 West Kennedy Boulevard, Suite 890 Tampa, Florida 33609 United States | |
| Phone | 813-553-6680 |
| Website | pacira.com |
Stock Details
| Ticker Symbol | PCRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001396814 |
| CUSIP Number | 695127100 |
| ISIN Number | US6951271005 |
| Employer ID | 51-0619477 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Charles A. Reinhart III, CPA, M.B.A. | Chief Financial Officer |
| Daryl Gaugler | Chief Operating Officer |
| Kristen Williams J.D. | Chief Administrative Officer and Secretary |
| Anthony Molloy III, Esq. | Chief Legal and Compliance Officer |
| David M. Stack | Advisor |
| Frank D. Lee | Chief Executive Officer and Director |
| Lauren Bullaro Riker | Principal Accounting Officer and Senior Vice President of Finance |
| Susan Mesco | Head of Investor Relations |
| Richard Kahr | Vice President of Human Resources |
| Dr. Jonathan Slonin M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 6, 2024 | 144 | Filing |
| Feb 29, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 29, 2024 | 10-K | Annual Report |
| Feb 29, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 19, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 4, 2024 | 8-K | Current Report |
| Dec 21, 2023 | 8-K | Current Report |
| Nov 13, 2023 | 144 | Filing |
| Nov 2, 2023 | 10-Q | Quarterly Report |